Pharma Admission

Pharma courses

pharma admission

pharma courses

Precautions & Suggestions:
1. A balanced diet of fresh, organic fruits and vegetables is best including some nuts and ghee.
2. Avoid cheeses and meats.
3. Add carrots and beets to your diet.
4. Avoid alcohol, marijuana and other drugs which directly damage brain tissue and affect memory.
5. Limit caffeine which stresses the nervous system, causing the mind to jump from thought to thought.

Cerebral Aging & Neurological Disorders is a vast topic & the work done on this topic will never be said complete, but still every effort is made to give best of best data related.

As per the work done on the topic it is being concluded that the, Cerebral Aging is a topic of present era since the ratio of geriatrics in population is on higher ratio, so to preserve the efficiency cerebral aging has to be controlled. Yes , the cerebral aging is the natural phenomena leading soon after puberty but still it causes drastic disorders in young when forced by some etiological factor known or not.

Various neurological disorders can cause additive problems with cerebral aging out of all Alzheimer’s disease is one leading a major concern.

Further it will be necessary to be abreast of knowledge that which medication or health aid, both prescription or nonprescription, can cause disorders of cognition. It should not be necessary to under treat the elderly and deprive them of the benefits of pharmacotherapy in order to avoid toxicity. A high level of vigilance and care should keep the therapy that is intended to extend life and enhance its quality from diminishing vital cognitive capacity in geriatrics.

Development of new technologies like Investigational neuropharmacologic techniques comprise a powerful and complementary collection of research tools for studying the effects of aging and disease on regional and specific measures of brain function. These have allowed us to characterize both the normal neurochemical changes that accompany successful aging and the accelerated or aberrant alterations seen in neuropsychiatric and behavioral dysfunction. Future work will carry the findings of the past decade into the realm of intervention.

Advancements in structural and functional imaging naturally complement those in molecular neurobiology and genetics, but we are just beginning to realize their potential combined power. For example, the recent availability of animal PET scanners presents the opportunity for the in vivo study of genetic models of disease, such as AD. Further, neuropharmacologic approaches to cognitive enhancement and slowing of dementia progression may be evaluated and monitored by imaging strategies. Indeed, the challenges posed by an increasingly aged population in industrialized nations are formidable, but may best be met by the combined application of developing technologies.

It is likely that just as there are behavioral routes to healthy bodies, there are behavioral routes to healthy minds. The linkage of studies of behavior across the life span will result in critical knowledge that will allow individuals to take control of their cognitive future and alter the neurobiological age of their minds. Such an outcome should offer huge rewards to both individual and to our society. A tremendous national investment in the neuroscience of cognitive aging combined with committed effort and generous cooperation among scholars is needed.

Age related cognitive treatment is always related to the lifestyle so proper lifestyle, the healthy one will lead to the normal aging(the rule of life-aging-death)without impairing the cognitive actions to large extent. So, advisable part is to stop using tobacco, have a nice breath full of oxygen to revitalize the cells of body, perform yoga and exercise.

Being in Oldies is not the age to panic for, it’s the most important part of life when  a person is able to give his/her experiences of life able to share that and thus forms the new world already having a knowledge from past experiences of elders.

So, while the Old people are not able to do physical work to large extent but their part in society is of enormous value, so to gain more and more from respected ones, their mental health should be cared for. So, cerebral aging is the topic for growth, to develop and for this continuous work and research is needed and world is moving that way too. Future is not ahead when elementary cause of cerebral aging will be identified, and treatment to nullify them in optimized manner will be developed.

1.Jernigan T, Archibald S, Berhow M, Sowell E, Foster D, Hesselink J. Cerebral structure on MRI, part I: localization of age-related changes. Biol Psychiatry. 1991;29:55-67.
2.Blatter D, Bigler E, Gale S, et al. Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. Am J Neuroradiol. 1995;16:241-251.
3.Miller AKH, Alston RL, Corsellis JAN. Variation with age in the volumes of grey and white matter in the cerebral hemispheres of man: measurements with an image analyser. Neuropathol Appl Neurobiol. 1980;6:119-132.
4.Joan T. Erber, Aging and Older Adulthood, 24 Aug 2011
5.Ito M, Hatazawa J, Yamaura H, Matsuzawa T. Age-related brain atrophy and mental deterioration—a study with computed tomography. Br J Radiol 1981;54:384-390.
6.Murphy D, DeCarli C, Schapiro M, Rapoport S, Horwitz B. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol. 1992;49:839-845.
7.Christiansen P, Larsson H, Thomsen C, Wieslander S, Henriksen O. Age dependent white matter lesions and brain volume changes in healthy volunteers. Acta Radiol. 1994;35:117-122.
8.Wahlund LO, Agartz I, Almqvist O, et al. The brain in healthy aged individuals: MR imaging. Radiology. 1990;174:675-679.
9.Golomb J, Kluger A, de Leon MJ, et al. Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Learn Mem. 1994;1:45-54.
10.DeCarli C, Murphy D, Gillette J, et al. Lack of age-related differences in temporal lobe volume of very healthy adults. Am J Neuroradiol. 1994;15:689-696.
11.Resnick S, Davatzikos C, Kraut M, Zonderman A. Longitudinal changes in MRI volumes in older adults. Presented at First International Meeting of the Alzheimer's Imaging Consortium 2000. Washington DC. 2000.
12.Autti T, Raininko R, Vanhanen SL, Kallio M, Santavuori P. MRI of the normal brain from early childhood to middle age. I. Appearances on T2- and proton density-weighted images and occurrence of incidental high-signal foci. Neuroradiology. 1994;36:644-648.
13.Horikoshi T, Yagi S, Fukamachi A. Incidental high-intensity foci in white matter on T2-weighted magnetic resonance imaging. Frequency and clinical significance in symptom-free adults. Neuroradiology. 1993;35:151-155
14.Longstreth W, Manolio T, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27:1274-1282.
15.Yetkin F, Fischer M, Papke R, Haughton V. Focal hyperintensities in cerebral white matter on MRI images of asymptomatic volunteers: correlation with social and medical histories. Am J Roentgenol. 1993;161:855-858.
16.Kalaria R. Cerebrovascular degeneration is related to amyloid protein deposition in Alzheimer's disease. Ann N Y Acad Sci. 1997;826:263-271.
17.Pantoni L, Garcia J. Cognitive impairment and cellular/vascular changes in cerebral white matter. Ann N Y Acad Sci. 1997;826:92-101.
18.Hatazawa J, Shimosegawa E, Satoh T, Toyoshima H, Okudera T. Subcortical hypoperfusion associated with asymptomatic white matter lesions on magnetic resonance imaging. Stroke. 1997;28:1944-1947.
19.Kuwabara Y, Ichiya Y, Sasaki M, et al. Cerebral blood flow and vascular response to hypercapnia in hypertensive patients with leukoaraiosis. Ann Nucl Med. 1996;10:293-298.
20.Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong M. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237-1239.
21.Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.
22.Little JT, Johnson DN, Minichiello M, Weingartner H, Sunderland T. Com-bined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses. Neuropsychopharmacology.1998;19:60-69.
23.Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull.1983;19:448-450.
24.Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
25.Folstein MF, Folstein SE, McHugh PH. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
26.Michelle Morgan, Herbs to Enhance Mental and Physical Performance, MediHerb a Phytotherapist’s perspective: No. 39 July 2004.
27.K. MIYAMOTO, Alternative Medicine for the Elderly, Editors: E. Paul Cherniack MD, Neil Cherniack PhD, Springer Link, 2003
28.Cerebral aging: integration of brain and behavioral models of cognitive function, Denise C. Park, PhD, Thad A. Polk, PhD, and Christy Marshuetz, PhD, Dialogues in Clinical Neuroscience, Sep. 2001 151-65


SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email